HUGE Snapshot
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD 201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also develops drugs for the treatment of pain, inflammation, and neurological disorders. It has license agreements with Epitech Group SpA.; and with Innovet Italia S.R.L. to develop veterinary drugs for the treatment of gastro-intestinal diseases in dogs and cats. The company was founded in 1998 and is headquartered in Toronto, Canada.
VALUATION DATA
Market Capitalization$2,020
Price to Sales0.00
Earnings per Share$0.0000
PE Ratio428232
PRICE DATA
Most Recent Close$1.5600
52 Week High$1.1147
52 Week Low$5.9001
50-Day Moving Average$1.28
200-Day Moving Average$1.9379
All data are from Alpha Vantage as of today. For more infomation on HUGE see Stock Dividend, Valuation, Price and Financial Data for Investors